National Pension Service Sells 68,324 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

National Pension Service lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 36.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 117,648 shares of the company’s stock after selling 68,324 shares during the period. National Pension Service owned about 0.14% of IDEXX Laboratories worth $48,640,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of IDXX. JFG Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $305,000. FFT Wealth Management LLC bought a new position in IDEXX Laboratories in the fourth quarter valued at approximately $227,000. Sterling Investment Advisors Ltd. bought a new position in IDEXX Laboratories in the fourth quarter valued at approximately $455,000. BankPlus Trust Department bought a new position in IDEXX Laboratories in the fourth quarter valued at approximately $60,000. Finally, IFP Advisors Inc boosted its stake in IDEXX Laboratories by 3.6% in the fourth quarter. IFP Advisors Inc now owns 903 shares of the company’s stock valued at $373,000 after acquiring an additional 31 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analysts Set New Price Targets

IDXX has been the topic of a number of recent research reports. Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Bank of America raised their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Finally, Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $533.75.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Trading Down 3.7 %

IDXX opened at $441.03 on Friday. The stock has a market capitalization of $35.87 billion, a P/E ratio of 41.33, a P/E/G ratio of 3.41 and a beta of 1.37. IDEXX Laboratories, Inc. has a 12 month low of $398.50 and a 12 month high of $583.39. The firm’s fifty day simple moving average is $434.82 and its 200 day simple moving average is $451.84. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.